Pharmaceutical industries News – 13 February 2026 | Pharma News Update

(Point-wise summary of major pharma headlines)

1) Biological E gets full WHO approval for polio vaccine

  • Biological E has received full WHO prequalification for its oral polio vaccine OPV2.
  • The company can now manage the entire vaccine manufacturing process in-house.
  • This follows earlier phase-1 approval granted in June 2024.
  • The firm has already supplied over 70 million doses globally.
  • The vaccine is designed to control outbreaks of vaccine-derived poliovirus.

2) USV acquires 79% stake in Wellbeing Nutrition

  • USV Pharma has acquired a 79% stake in Wellbeing Nutrition.
  • The deal values the company at around ₹1,583 crore.
  • Founder Avnish Chhabria will retain a stake and continue operations.
  • The acquisition strengthens USV’s entry into:
  • Nutraceuticals
  • Preventive healthcare
  • Consumer wellness segments

3) Sanofi replaces CEO after R&D setbacks

  • Sanofi has removed CEO Paul Hudson after major R&D disappointments.
  • The company appointed Bélen Garijo of Merck KGaA as successor.
  • Key reason:
  • Failure to offset revenue loss from key drug patent expiries.
  • Multiple late-stage trial setbacks.
  • New leadership will focus on:
  • R&D productivity
  • Innovation capabilities
  • Strategic execution

4) Biocon Q3 profit jumps over fivefold

  • Biocon reported a more than fivefold increase in Q3 net profit to ₹144 crore.
  • Growth driven by:
  • Strong performance in generics.
  • Expansion of biosimilars business.
  • Quarterly revenue rose to about ₹4,173 crore, up from ₹3,821 crore last year.

5) Abbott reports 4% rise in Q3 profit

  • Abbott India posted a 4% increase in Q3 net profit to ₹376 crore.
  • Revenue from operations rose to ₹1,724 crore.
  • Growth reflects stable domestic demand and portfolio performance.

6) Natco Pharma posts Q3 profit growth

  • Natco Pharma reported Q3 net profit of ₹151.3 crore, up from ₹132.4 crore last year.
  • Quarterly revenue reached ₹647.3 crore.
  • The board approved an interim dividend of ₹1.50 per share.

7) India’s medical devices market to reach $50 billion by 2030

  • India’s medical devices sector is projected to grow from $15.2 billion (2025) to $50.1 billion by 2030.
  • Expected CAGR: 26.9%.
  • Growth drivers:
  • Government incentives and policies.
  • Expansion of medical device parks.
  • Increasing domestic demand.
  • India currently ranks 4th in Asia in the medical devices market.

8) IIL to set up new formulations facility in Rajasthan

  • Insecticides India Ltd (IIL) plans to establish a formulations plant in Rajasthan.
  • Estimated investment: around ₹300 crore.
  • The facility will:
  • Expand manufacturing capacity.
  • Support export and domestic growth.

Disclaimer:

This news summary is compiled from publicly available media reports and industry sources for informational purposes only. It does not constitute medical, legal, or investment advice. Readers should refer to official announcements, regulatory filings, and professional advisors before making any decisions based on this information.


APPLY FOR PCD PHARMA FRANCHISE